Table of Content

1. US Alzheimer’s Disease Drug Market Overview


2. US - Approved Alzheimer’s Disease Drugs by Class
2.1 Cholinesterase Inhibitors
2.2 NMDA Receptor Agonist


3. US - New Emerging Therapies in Alzheimer’s Disease
3.1 Monoclonal Antibody
3.2 Novel NMDA Receptor Agonists
3.3 Small Molecules Drug
3.4 Oral Semaglutide


4. US - Alzheimer’s Disease Generic & Biosimilar Drug Market Landscape
4.1 Current Scenario & Price Differential
4.2 Reimbursement Laws & Regulations


5. Anti-Alzheimer’s Disease Drugs Classification


6. Acetylcholinesterases Inhibitor: US Market Availability, Dosage, Patent & Price Insight
6.1 Razadyne (Brand Drug)
6.2 Razadyne ER (Branded)
6.3 Aricept (Brand Drug)
6.4 Aricept ODT (Branded)
6.5 Reminyl (Branded)
6.6 Exelon (Brand Drug)
6.7 Namzaric (Brand Drug)



7. N-methyl-D-aspartate Inhibitors: US Market Availability, Dosage, Patent & Price Insight
7.1 Namenda (Brand Drug)
7.2 Namenda XR (Branded)


8. Approved Generic Drugs for Alzheimer’s: US Market Availability, Dosage & Price Insight
8.1 Galantamine (Generic Drug)
8.2 Donepzil (Generic Drug)
8.3 Rivastigmine (Generic Drug)
8.4 Memantine (Generic Drug)
8.5 Ergoloid Mesylates


9. US - Alzheimer’s Disease Drugs Clinical Trials Overview
9.1 By Biomarket
9.2 By Formulation
9.3 By Organization
9.4 By Phase
9.5 By Patient Segment


10. US - Alzheimer’s Disease Drug Clinical Pipeline By Company, Indication & Phase
10.1 Unknown
10.2 Research
10.3 Preclinical
10.4 Clinical
10.5 Phase-I
10.6 Phase-I/II
10.7 Phase-II
10.8 Phase-II/III
10.9 Phase-III
10.10 Preregistration
10.11 Registered


11. US - Marketed Alzheimer’s Disease Drugs Clinical Insight
11.1 Razadyne
11.2 Namenda
11.3 Exelon Patch
11.4 Amyvid
11.5 Namzaric
11.6 Aricept
11.7 NeuraCeq
11.8 Vizamyl
11.9 Cognex


12. US Alzheimer’s Disease Drug Market Dynamics
12.1 US Alzheimer’s Market Favourable Parameters
12.2 US Alzheimer’s Drug Market Challenges


13. US Alzheimer Drug Market Future Prospects


14. Competitive Landscape
14.1 Allergan
14.2 Alvogen
14.3 Dr. Reddy Laboratories
14.4 Eisai Co Ltd
14.5 Hoffmann- La Roche Ltd
14.6 Jassen Pharmaceuticals
14.7 Lupin
14.8 Mylan
14.9 Novartis AG
14.10 Sun Pharma
14.11 Teva Pharmaceuticals